Hospital to Home Study: Trial to Optimize Transitions and Address Disparities in Asthma Care
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Kavita Parikh
- Study ID
- NCT05991115
- Status
- Recruiting
Conditions
- Asthma
- Asthma in Children
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Years - 12 Years
- Healthy Volunteers
- Not accepted
Interventions
- Hospital to Home Transition (H2H) — BEHAVIORALThe intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
Study Details
Caregiver-child dyads will be recruited during child's hospital admission for asthma exacerbation. Recruitment sites will be mainly Children's National Hospital Sheikh Zayed campus, as well as regional partners: Holy Cross Hospital, and Mary Washington Hospital. After enrollment, baseline data will be collected from caregiver. Caregiver-child dyads will be randomized (1:1 ratio) into the control arm or intervention arm. Control arm will receive the standard of care after hospital discharge. Intervention arm will receive the SOC plus an asthma navigator support after hospital discharge. Caregivers in both arms will complete data collection surveys (either in-person or via telehealth) at 3-,6-, 9-, and 12- month post enrollment.
Key Dates
- Start date
- Jan 22, 2024
- Status verified
- Mar 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 340 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- No Intervention: Standard of CareControl arm will receive the standard of care (SOC) after hospital discharge.
- Experimental: Hospital to Home Transition (H2H)The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
Primary Outcome Measure
Number of Re-admissions [ Time Frame: 3, 6, 9, 12 months ]
Central Contacts
- Kavita Parikh, MD MSHS2024766366
- Alicia Mathis2024764698
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 |
Find similar trials in Washington D.C., DC
Related Studies
- Registry of Asthma Characterization and Recruitment 3 (RACR3)Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Aurora, Colorado
- Omalizumab Before Onset of ExacerbationsPHASE2 · Recruiting · Children's National Research Institute · Washington D.C., District of Columbia
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)PHASE3 · Recruiting · AstraZeneca · Mobile, Alabama
- Protocol CAUSE-03 / CHEETAHRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Aurora, Colorado